Digest Network Come funziona
Network
/
Società
St
Non verificato

Strand Therapeutics

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieOncologiaSalute

8 comunicati stampa

Guarda tutti i comunicati
15/12/2025
Eventi
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Strand Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Strand Therapeutics
Emittente
Business Wire
1.00
0
02/12/2025
Strand Therapeutics Appoints Jeb Keiper to Board of Directors
Fonte
Strand Therapeutics
Emittente
Business Wire
1.00
0
05/11/2025
Strand Therapeutics Promotes Prashant Nambiar to Chief Scientific Officer and Appoints Ethan Cash as Senior Vice President, Head of Portfolio Management and Program Development
Fonte
Strand Therapeutics
Emittente
Business Wire
1.00
0
21/08/2025
Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer
Fonte
Strand Therapeutics
Emittente
Business Wire
1.00
0
21/08/2025
Strand Therapeutics Appoints Dr. Jason J. Luke as Chief Medical Officer
Fonte
Strand Therapeutics
Emittente
Business Wire
1.00
0
07/08/2025
Oncologia
Salute
Biotecnologia
Medicina - Varie
Scienza
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Fonte
Strand Therapeutics
Emittente
Business Wire
1.00
0
28/05/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting
Fonte
Strand Therapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Industria
Salute
Biotecnologia
Sanità
Scienza
Potential First-in-Class Data from Preclinical Program for STX-003, a Programmable mRNA Therapy to Treat Solid Tumor Cancers
Fonte
Strand Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0